O	0	1	A
O	2	12	randomized
O	12	13	,
O	14	20	double
O	20	21	-
O	21	28	blinded
O	29	36	placebo
O	36	37	-
O	37	47	controlled
O	48	56	clinical
O	57	62	trial
O	63	65	of
O	66	69	the
O	70	77	routine
O	78	81	use
O	82	84	of
B-intervention	85	97	preoperative
I-intervention	98	108	antibiotic
I-intervention	109	120	prophylaxis
O	121	123	in
O	124	132	modified
O	133	140	radical
O	141	151	mastectomy
O	151	152	.

O	153	156	The
O	157	170	effectiveness
O	171	173	of
O	174	184	antibiotic
O	185	196	prophylaxis
O	197	200	for
O	201	211	prevention
O	212	214	of
B-condition	215	223	surgical
I-condition	224	228	site
I-condition	229	238	infection
I-condition	239	240	(
I-condition	240	243	SSI
I-condition	243	244	)
O	245	254	following
O	255	263	specific
O	264	269	types
O	270	272	of
O	273	279	breast
O	280	286	cancer
O	287	294	surgery
O	295	302	remains
O	303	312	uncertain
O	312	313	.

O	314	318	This
O	319	324	study
O	325	333	assessed
O	334	337	the
O	338	351	effectiveness
O	352	354	of
O	355	366	prophylaxis
O	367	369	in
O	370	378	modified
O	379	386	radical
O	387	397	mastectomy
O	398	399	(
O	399	402	MRM
O	402	403	)
O	403	404	.

B-eligibility	405	410	Women
I-eligibility	411	421	undergoing
I-eligibility	422	425	MRM
I-eligibility	426	429	for
I-eligibility	430	436	breast
I-eligibility	437	443	cancer
O	444	448	were
O	449	458	recruited
O	458	459	.

O	460	465	Women
O	466	470	were
O	471	479	excluded
O	480	483	who
O	484	487	had
O	488	496	diabetes
O	497	505	mellitus
O	505	506	,
O	507	513	severe
O	514	526	malnutrition
O	527	529	or
O	530	535	known
O	536	543	allergy
O	544	546	to
O	547	561	cephalosporins
O	561	562	;
O	563	567	were
O	568	577	receiving
O	578	592	corticosteroid
O	593	600	therapy
O	601	603	or
O	604	608	were
O	609	616	treated
O	617	621	with
O	622	633	antibiotics
O	634	640	within
O	641	644	one
O	645	649	week
O	650	655	prior
O	656	658	to
O	659	666	surgery
O	666	667	;
O	668	672	were
O	673	682	scheduled
O	683	686	for
O	687	699	simultaneous
O	700	706	breast
O	707	721	reconstruction
O	722	724	or
O	725	734	bilateral
O	735	747	oophorectomy
O	747	748	;
O	749	752	had
O	753	761	existing
O	762	767	local
O	768	777	infection
O	777	778	.

O	779	791	Participants
O	792	796	were
O	797	807	randomized
O	808	810	to
O	811	818	receive
O	819	825	either
B-intervention	826	837	intravenous
I-intervention	838	847	cefazolin
O	848	849	1
O	850	851	g
O	852	854	or
B-control	855	862	placebo
O	863	869	within
O	870	872	30
O	873	876	min
O	877	882	prior
O	883	885	to
O	886	890	skin
O	891	899	incision
O	899	900	.

O	901	909	Standard
O	910	914	skin
O	915	926	preparation
O	927	930	and
O	931	940	operative
O	941	950	technique
O	951	954	for
O	955	958	MRM
O	959	963	were
O	964	971	carried
O	972	975	out
O	975	976	.

O	977	983	Wounds
O	984	988	were
O	989	997	assessed
O	998	1001	for
O	1002	1005	SSI
O	1006	1009	and
O	1010	1015	other
O	1016	1029	complications
O	1030	1036	weekly
O	1037	1040	for
O	1041	1043	30
O	1044	1048	days
O	1048	1049	.

O	1050	1051	A
O	1052	1057	total
O	1058	1060	of
B-total-participants	1061	1064	254
O	1065	1070	women
O	1071	1075	were
O	1076	1085	recruited
O	1085	1086	.

O	1087	1090	Age
O	1090	1091	,
O	1092	1100	clinical
O	1101	1106	stage
O	1106	1107	,
O	1108	1113	prior
O	1114	1126	chemotherapy
O	1126	1127	,
O	1128	1131	and
O	1132	1141	operative
O	1142	1146	time
O	1147	1151	were
O	1152	1159	similar
O	1160	1163	for
O	1164	1174	antibiotic
O	1175	1178	and
O	1179	1186	placebo
O	1187	1193	groups
O	1193	1194	.

O	1195	1198	The
B-outcome	1199	1206	overall
I-outcome	1207	1216	incidence
I-outcome	1217	1219	of
I-outcome	1220	1223	SSI
O	1224	1227	was
O	1228	1230	14
O	1230	1231	.
O	1231	1232	2
O	1233	1234	%
O	1234	1235	.

O	1236	1241	There
O	1242	1246	were
O	1247	1249	no
O	1250	1261	significant
O	1262	1273	differences
O	1274	1276	in
O	1277	1280	the
B-outcome	1281	1290	infection
I-outcome	1291	1295	rate
O	1296	1300	over
O	1301	1304	the
O	1305	1307	30
O	1307	1308	-
O	1308	1311	day
O	1312	1318	follow
O	1318	1319	-
O	1319	1321	up
O	1322	1328	period
O	1329	1336	between
O	1337	1340	the
O	1341	1348	placebo
O	1349	1352	and
O	1353	1363	antibiotic
O	1364	1370	groups
O	1371	1372	(
B-cv-bin-percent	1372	1374	15
I-cv-bin-percent	1375	1376	%
O	1377	1379	vs
B-iv-bin-percent	1380	1382	13
I-iv-bin-percent	1382	1383	.
I-iv-bin-percent	1383	1384	4
I-iv-bin-percent	1385	1386	%
O	1386	1387	;
O	1388	1389	p
O	1390	1391	=
O	1392	1393	0
O	1393	1394	.
O	1394	1397	719
O	1397	1398	)
O	1399	1401	or
O	1402	1404	at
O	1405	1409	each
O	1410	1414	week
O	1414	1415	.

O	1416	1419	The
O	1420	1428	majority
O	1429	1431	of
O	1432	1435	SSI
O	1436	1440	were
O	1441	1447	either
O	1448	1458	cellulitis
O	1459	1461	or
O	1462	1473	superficial
O	1474	1483	infection
O	1484	1487	for
O	1488	1492	both
O	1493	1499	groups
O	1499	1500	.

O	1501	1506	There
O	1507	1511	were
O	1512	1514	no
O	1515	1526	significant
O	1527	1538	differences
O	1539	1546	between
O	1547	1553	groups
O	1554	1556	in
O	1557	1567	treatments
O	1568	1576	required
O	1577	1580	for
B-outcome	1581	1584	SSI
O	1584	1585	,
B-outcome	1586	1595	incidence
I-outcome	1596	1598	of
I-outcome	1599	1607	hematoma
O	1608	1610	or
B-outcome	1611	1617	seroma
O	1617	1618	.

O	1619	1622	The
O	1623	1631	findings
O	1632	1634	of
O	1635	1639	this
O	1640	1645	study
O	1645	1646	,
O	1647	1652	alone
O	1653	1656	and
O	1657	1661	when
O	1662	1666	meta
O	1666	1667	-
O	1667	1675	analyzed
O	1676	1680	with
O	1681	1685	data
O	1686	1690	from
O	1691	1698	studies
O	1699	1701	in
O	1702	1709	similar
O	1710	1718	surgical
O	1719	1730	populations
O	1730	1731	,
O	1732	1734	do
O	1735	1738	not
O	1739	1746	support
O	1747	1750	the
O	1751	1754	use
O	1755	1757	of
O	1758	1768	antibiotic
O	1769	1780	prophylaxis
O	1781	1783	in
O	1784	1787	MRM
O	1787	1788	.
